ArticleScience advances2023
Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 74 citations in OpenAlex.
- In situ bioactive nanocoating enables transocular delivery of permeable drug for dual-location intervention of ocular surface and fundus disorders.Bioactive materials · 2027Article
- Nano-drops of biomimetic macromolecular drugs based on macrophage membranes for targeted treatment of fundus diseases.Materials today. Bio · 2026Article
- Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.Journal of nanobiotechnology · 2026Review
- Chitosan-Functionalized Liposome-Mediated Fundus Delivery of Epigallocatechin-3-Gallate for Diabetic Retinopathy Therapy.Advanced healthcare materials · 2026Article
- The Promise of Single-Domain Antibodies as Ocular Therapeutics: A Narrative Review.International journal of molecular sciences · 2026Review
- Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye.Translational vision science & technology · 2026Article
- Development of Miniprotein Binders to Inhibit VEGF-Induced Corneal Neovascularization.Investigative ophthalmology & visual science · 2026Article
- GSH-Responsive PBAE Polymers for IL-12 mRNA Delivery in Melanoma Immunotherapy.Investigative ophthalmology & visual science · 2026Article
- ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy.Materials today. Bio · 2026Article
- Engineering Strategies of Colloidal Drug Delivery Systems, a Rising Star in Ocular Neovascular Diseases.Molecules (Basel, Switzerland) · 2026Review
- Harnessing semen-derived exosomes for noninvasive fundus drug delivery: A paradigm for exosome-based ocular fundus therapeutics.Science advances · 2026Article
- Aggregation-Induced-Emission Luminogens Functionalized MXene Nanosheets for Stimuli-Responsive Hydrogel in Pyroptosis-Mediated Choroidal Melanoma Therapy.Nano-micro letters · 2026Article
- Ciliary Defects in Inherited Retinal Diseases.Advanced genetics (Hoboken, N.J.) · 2026Review
- Advances in microneedle Technology for Treatment of retinal degenerative diseases: a narrative review.Biomedical microdevices · 2026Review
- Systemic targeting of aberrant neovascular tufts using trehalose-dendrimer nanocarriers for the treatment of proliferative retinopathies.Theranostics · 2026Article
- Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization.International journal of pharmaceutics: X · 2025Article
- Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Poly-(L-homoarginine) for the non-invasive treatment of endophthalmitis.Materials today. Bio · 2025Article
- A Serum Resistant Polymer with Exceptional Endosomal Escape and mRNA Delivery Efficacy for CRISPR Gene Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Peptide-Bound Aflibercept Eye Drops for Treatment of Neovascular Age-Related Macular Degeneration in Nonhuman Primates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic antibodies are extensively used to treat fundus diseases by intravitreal injection, as eyedrop formulation has been rather challenging due to the presence of ocular barriers. Here, an innovative penetrating carrier was developed for antibody delivery in eyedrop formulations. We found that fluorocarbon-modified chitosan (FCS) would self-assemble with proteins to form nanocomplexes, which could effectively pass across the complicated ocular structure to reach the posterior eye segments in both mice and rabbits. In a choroidal melanoma-bearing mouse model, eyedrops containing FCS/anti-PDL1 could induce stronger antitumor immune responses than those triggered by intravenous injection of anti-PDL1. Moreover, in choroidal neovascularization-bearing mouse and rabbit models, FCS/anti-VEGFA eyedrops effectively inhibited vascular proliferation, achieving comparable therapeutic responses to those observed with intravitreal injection of anti-VEGFA. Our work presents an effective delivery carrier to treat fundus diseases using eyedrop of therapeutic proteins, which may enable at-home treatment of many eye diseases with great patient compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.